Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 1251–1300 of 76231
On June 29, 2026, the Board of Directors (the “Board”) of ITT Inc. (the “Company”) elected Bertrand Loy and Kevin Wheeler as directors of the Company, effective August 1, 2026.
Fathom Holdings Inc. (the “Company”) appointed Adam Rothstein and Daniel Weinmann as the Company’s Interim Chief Executive Officer and Chief Financial Officer, respectively.
Fathom Holdings Inc. (the “Company”) appointed Adam Rothstein and Daniel Weinmann as the Company’s Interim Chief Executive Officer and Chief Financial Officer, respectively.
appointed current Northfield directors John P. Connors, Jr., Timothy C. Harrison, Steven M. Klein, and Paul V. Stahlin to the Company’s board of directors as the Northfield Continuing Directors, subject to and effective upon the completion of the Merger.
appointed current Northfield directors John P. Connors, Jr., Timothy C. Harrison, Steven M. Klein, and Paul V. Stahlin to the Company’s board of directors as the Northfield Continuing Directors, subject to and effective upon the completion of the Merger.
appointed current Northfield directors John P. Connors, Jr., Timothy C. Harrison, Steven M. Klein, and Paul V. Stahlin to the Company’s board of directors as the Northfield Continuing Directors, subject to and effective upon the completion of the Merger.
appointed current Northfield directors John P. Connors, Jr., Timothy C. Harrison, Steven M. Klein, and Paul V. Stahlin to the Company’s board of directors as the Northfield Continuing Directors, subject to and effective upon the completion of the Merger.
On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
appointed A. Jayson Adair, the Company’s current Executive Chairman, as Chief Executive Officer and principal executive officer (the “CEO Transition”), effective as of July 31, 2026
Jeffrey Liaw, who will step down as Chief Executive Officer and principal executive officer and will resign from the Board, each effective as of the Transition Date. Mr. Liaw’s decision to resign was not the result of any disagreement
appointed Mr. Jesse G. Singh as Chief Executive Officer of the Company (“CEO”) and as a Class I member of the Board, effective on June 29, 2026.
appointed Mr. David V. Barry, the Company’s Interim Chief Executive Officer, as Executive Vice President and Chief Operating Officer of the Company (“COO”), also effective on June 29, 2026.
appointed Mr. Jesse G. Singh as Chief Executive Officer of the Company (“CEO”) and as a Class I member of the Board, effective on June 29, 2026.
mutually agreed with Mr. Paul Pinkston that he step down from the position of Chief Accounting Officer of, and to terminate his employment with, the Company.
On June 24, 2026, Nathan D. DeBacker ceased to serve as Chief Financial Officer, Principal Accounting Officer and Treasurer of the Registrant, effective June 24, 2026.
On June 24, 2026, the Board appointed David Thompson to serve as Chief Financial Officer, Principal Accounting Officer and Treasurer of the Registrant, effective June 24, 2026.
Deborah Flint I Director
Craig Arnold III Chairman of the Company Board
Jake Wasserman and Thilo Huber resigned from their positions as directors on the Company Board.
General (Retired) David Goldfein I Director
Michelle Seitz II Director
The Honorable Dr. William B. Roper Jr. II Director
James Currier III Director
William Ayer II Director
David Denton II Director
D. Scott Davis I Director
Mark Reuss III Director
Jake Wasserman and Thilo Huber resigned from their positions as directors on the Company Board.
Pascal Desroches, who was previously appointed as a member and the chair of the Audit Committee as of June 14, 2026
On June 29, 2026, Genesco Inc. (the “Company”) announced the appointment of Jonathan Collins as Senior Vice President, Finance and Chief Financial Officer.
As such, as of the Effective Date, Ms. Vaughn will no longer serve as the Company’s Interim Chief Financial Officer and principal financial officer.
Mr. James Currier resigned as an executive officer of the Company, effective as of immediately prior to and conditioned upon the consummation of the Spin-Off.
On June 26, 2026, James E. Davison, a member of the board of directors (the “Board”) of our general partner notified the Board of his retirement, effective June 26, 2026.
On June 25, 2026, in connection with Daniel (Dani) Bendheim’s appointment to the role of Chief Executive Officer and President of the Company effective July 1, 2026
has appointed Jason Knoblauch as the Company’s Chief Financial Officer, effective July 6, 2026 (the "Transition Date").
He will succeed Jill McConnell, who is stepping down as Chief Financial Officer on the Transition Date but intends to remain employed with the Company for a transition period.
On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026.
On June 22, 2026, Atara Biotherapeutics, Inc. (the “Company”) notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026.
On June 22, 2026, the board of directors (the “Board”) of Willow Lane Acquisition Corp. II, a Cayman Islands exempted company (the “Company”), appointed Joseph Samuels to serve as a Class I director on the Board, effective immediately.
Kristen L. Soler, Executive Vice President, Chief Human Resources Officer of Advance Auto Parts, Inc. (the “Company”) will be leaving the Company to pursue other opportunities.
On June 25, 2026, the Federal Home Loan Bank of Chicago (the “Bank”) received notification from Dean A. Ahlers that he is resigning from the Bank’s Board of Directors (the “Board”), effective immediately.
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
As of June 22, 2026, member director Kevin D. Miller ceased serving as president and chief executive officer of Profile Bank, in Rochester, New Hampshire.
On June 23, 2026, Gregory M. Larson, Vice President – Accounting & Controller of Expand Energy Corporation (the “Company”) informed the Company of his intention to resign from the Company.
Marcel Teunissen, the Company’s current Executive Vice President and Chief Financial Officer, has assumed the duties as principal accounting officer of the Company on an interim basis, effective June 23, 2026, while the Company conducts a search for a permanent Vice President – Accounting & Controller.
On June 25, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death or removal.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.